Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

The Mechanisms of neuronal silencing in Alzheimer’s Disease – investigation of cellular and network mechanisms in mouse models of β-amyloidosis

Project description

Neuronal silencing in Alzheimer’s disease

Alzheimer’s disease (AD) is characterised by profound disturbances in neuronal activity and in the way brain cells communicate. Early disease stages are marked by neuronal hyperactivity, while later stages show widespread neuronal silencing. Although this silencing contributes to cognitive decline, it remains poorly understood. The ERC-funded MONSil-AD project aims to uncover the mechanisms driving neuronal silencing in AD. Researchers will investigate three possible causes: loss of connections between neurons, harmful accumulation of the tau protein inside cells and immune signalling in the brain. Using advanced brain imaging in mouse models, MONSil-AD aims to reveal how these processes interact, opening paths to neuronal activity-based screening and treatment strategies.

Objective

Alzheimer’s disease (AD) is defined by pathological brain changes, including the accumulation of β-amyloid and tau deposits over decades. In addition, data in human patients and rodent models indicate that neuronal dysfunctions, i.e. altered action potential firing rates, are further hallmarks of AD. Two forms of neuronal dysfunctions exist - neuronal hyperactivity at early stages, followed later by neuronal silencing. The causes of neuronal hyperactivity have been widely studied. However, the mechanisms of neuronal silencing are still incompletely understood, likely due to the high complexity of interdependent brain changes in late AD stages.
MONSil-AD aims to unravel the multifactorial pathways leading to neuronal silencing in AD mouse models. My preliminary data indicate that silencing co-occurs with emergent tauopathy, loss of dendritic spines, and decreased presynaptic inputs in mouse models of β-amyloidosis. Moreover, the soluble ectodomain of the microglial ‘triggering receptor expressed on myeloid cells 2’ (sTREM2), which is upregulated in AD, suppresses neuronal activity. Based on these findings, I will investigate whether synaptic uncoupling from the circuit causes the silencing of individual neurons (aim 1) and test if intracellular tau accumulation silences neurons on a cellular level (aim 2). In addition, I will explore the contribution of sTREM2 to neuronal silencing in AD (aim 3) and the interactions between the three mechanisms.
To reach the ambitious aims of MONSil-AD, I have implemented cutting-edge in vivo two-photon imaging techniques and developed specialized protocols enabling me, for the first time, to provide a comprehensive picture of the mechanisms leading to neuronal silencing in AD. In addition, MONSil-AD may have direct clinical implications as a basis for the development of an activity-based screening tool for the early non-invasive detection of AD and the development of targeted treatment strategies to prevent neuronal silencing.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-STG

See all projects funded under this call

Host institution

KLINIKUM DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (TUM KLINIKUM)
Net EU contribution
€ 1 482 666,25
Address
ISMANINGER STRASSE 22
81675 Muenchen
Germany
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 482 666,25

Beneficiaries (1)